Last reviewed · How we verify
Placebo for micronized progesterone
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control comparator in clinical trials for micronized progesterone formulations.
At a glance
| Generic name | Placebo for micronized progesterone |
|---|---|
| Sponsor | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebos are inert formulations used as control comparators in clinical trials to distinguish true drug effects from placebo response. In this case, it serves as a control for micronized progesterone studies, allowing researchers to measure the actual therapeutic benefit of the active hormone independent of psychological or expectation-based effects.
Approved indications
- Control comparator in clinical trials for micronized progesterone formulations
Common side effects
- Placebo response (non-specific symptom improvement)
Key clinical trials
- A Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix (PHASE3)
- Chinese Herbal Medicine (New "Shoutai Wan") and/or Oral Progesterone Intervention Trial for Threatened Miscarriage (PHASE3)
- Cyclical Neuroactive Steroid Changes, Arousal, and Proximal Suicide Risk: An Experimental Approach (PHASE4)
- Hyperandrogenemia and Altered Day-night LH Pulse Patterns (EARLY_PHASE1)
- Menopausal HT for Women Living With HIV (HoT) (PHASE4)
- The Role of Estrogen in the Neurobiology of Eating Disorders (PHASE2)
- Examining the Effects of Estradiol on Neural and Molecular Response to Reward (PHASE4)
- To Investigate Efficacy and Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: